Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue

To remain shielded from political forces that could change incentives, pharmaceutical industry must adopt 'a certain set of values,' US...

More From BioPortfolio on "Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue"